Predicting response to neoadjuvant therapy with glucose transporter-1 in breast cancer.

Seda Duman Öztürk Çiğdem Öztürk Oguzhan Okcu Gokce Askan Bayram Sen Recep Bedir

Published in: Revista da Associacao Medica Brasileira (1992) (2023)

Glucose transporter-1 has the potential to be a biomarker that can be evaluated more objectively as an alternative to Ki-67 labeling index in evaluating the response to treatment in patients receiving neoadjuvant therapy.

Keyphrases

rectal cancer
lymph node
locally advanced
blood glucose
physical activity
stem cells
type diabetes
metabolic syndrome
radiation therapy
young adults
risk assessment
skeletal muscle
adipose tissue
human health